TAX and HBZ: hFc Ɣ ۱ proteins as targets for passive immunotherapy

Publish Year: 1401
نوع سند: مقاله ژورنالی
زبان: English
View: 198

This Paper With 11 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-25-5_006

تاریخ نمایه سازی: 21 خرداد 1401

Abstract:

Objective(s): Human T leukemia virus type one (HTLV-۱) causes two life-threatening diseases in around five percent of infected subjects, a T cell malignancy and a neurodegenerative disease. TAX and HBZ are the main virulence agents implicated in the manifestation of HTLV-۱–associated diseases. Therefore, this study aims to produce these HTLV-۱ factors as recombinant Fc fusion proteins to study the structures, their immunogenic properties as vaccines, and their capability to produce specific neutralization antibodies.Materials and Methods: TAX and HBZ sequences were chosen from the NCBI-nucleotide database, then designed as human Fc chimers and cloned into Pichia pastoris. Produced proteins were purified by HiTrap affinity chromatography and subcutaneously injected into rabbits. Rabbit Abs were purified by batch chromatography, and their neutralization activities for the HTLV-۱-infected MT-۲ cell line were assessed. Furthermore, the protective abilities of recombinant proteins were evaluated in Tax or HBZ immunized rabbits by MT-۲ cell line inoculation and measurement of HTLV-۱-proviral load.Results: Specific Abs against Tax and HBZ can eliminate ۲ million MT-۲ cells in ۱/۱۰۰۰ dilution in vitro. In challenging assays, the immunization of the animals using Tax or HBZ had no protective activity as HTLV-۱ PVL was still positive.Conclusion: The result suggests that recombinant TAX and HBZ: hFcγ۱ proteins can produce a proper humoral immune response. Therefore, they could be considered a passive immunotherapy source for HTLV-۱-associated diseases, while total TAX and HBZ proteins are unsuitable as HTLV-۱ vaccine candidates. 

Authors

Mohammad Akbarin

Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Houshang Rafatpanah

Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Saman Soleimanpour

Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abbas Amini

Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran

Amirali Arian

Animal Laboratory, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Arman Mosavat

Blood Borne Infections Research Center, Academic Center for Education, Culture, and Research (ACECR), Razavi Khorasan, Mashhad, Iran

Seyed Abdolrahim Rezaee

Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Eusebio-Ponce E, Anguita E, Paulino-Ramirez R, Candel FJ. HTLV-۱ infection: ...
  • Khan MY, Khan IN, Farman M, Al Karim S, Qadri ...
  • Taylor GP. The epidemiology of HTLV-I in Europe. J Acquir ...
  • Araujo AQ, Silva MT. The HTLV-۱ neurological complex. Lancet Neurol ...
  • Garcia I, Hennington É A. HTLV: a stigmatizing infection? Cad ...
  • ۹.Watanabe T. HTLV-۱-associated diseases. Int J Hematol ۱۹۹۷; ۶۶:۲۵۷-۲۷۸ ...
  • Rodríguez-Zúñiga MJM, Cortez-Franco F, Qujiano-Gomero E. Adult T-cell leukemia/lymphoma. Review ...
  • Phillips AA, Harewood JCK. Adult T Cell leukemia-lymphoma (ATL): state ...
  • Mehta-Shah N, Ratner L, Horwitz SM. Adult T-Cell leukemia/lymphoma. J ...
  • Mirhosseini A, Mohareri M, Arab R, Rezaee SA, Shirdel A, ...
  • Tarokhian H, Rahimi H, Mosavat A, Shirdel A, Rafatpanah H, ...
  • Matsuoka M, Mesnard JM. HTLV-۱ bZIP factor: the key viral ...
  • Al-Saleem J DW, Martinez MP, Shkriabai N, Kvaratskhelia M, Ratner ...
  • Fochi S, Mutascio S, Bertazzoni U, Zipeto D, Romanelli MG. ...
  • Rauch DA, Ratner L. Targeting HTLV-۱ activation of NFκB in ...
  • Wurm T, Wright DG, Polakowski N, Mesnard J-M, Lemasson I. ...
  • Mozhgani SH, Jaberi N, Rezaee SA, Bustani R, Jazayeri SM, ...
  • Zhao T. The role of HBZ in HTLV-۱-induced oncogenesis. Viruses ...
  • Katsuya H, Ishitsuka K. Treatment advances and prognosis for patients ...
  • Torshizi R, Ghayour Karimani E, Etminani K, Akbarin MM, Jamialahmadi ...
  • Marino-Merlo F, Balestrieri E, Matteucci C, Mastino A, Grelli S, ...
  • de Thé G, Bomford R. An HTLV-I vaccine: why, how, ...
  • Arina A, Tirapu I, Alfaro C, Rodríguez-Calvillo M, Mazzolini G, ...
  • Colovos C, Yeates TO. Verification of protein structures: patterns of ...
  • Lovell SC, Davis IW, Arendall WB ۳rd, de Bakker PI, ...
  • Gupta R, Brunak S. Prediction of glycosylation across the human ...
  • Karbalaei Zadeh Babaki M, Taghiabadi M, Soleimanpour S, Saleh Moghadam ...
  • Baghani AA, Soleimanpour S, Farsiani H, Mosavat A, Yousefi M, ...
  • Shuh M, Beilke M. The human T-cell leukemia virus type ...
  • Kannagi M, Hasegawa A, Nagano Y, Iino T, Okamura J, ...
  • Martin F, Taylor GP, Jacobson S. Inflammatory manifestations of HTLV-۱ ...
  • Moreno-Ajona D, Yuste JR, Martín P, Gállego Pérez-Larraya J. HTLV-۱ ...
  • Olindo S, Belrose G, Gillet N, Rodriguez S, Boxus M, ...
  • Lynch MP, Kaumaya PT. Advances in HTLV-۱ peptide vaccines and ...
  • Datta-Mannan A, Witcher DR, Lu J, Wroblewski VJ. Influence of ...
  • Peter H-H, Ochs HD, Cunningham-Rundles C, Vinh DC, Kiessling P, ...
  • Kannian P, Yin H, Doueiri R, Lairmore M, Fernandez S, ...
  • Begum N, Horiuchi S, Tanaka Y, Yamamoto N, Ichiyama K. ...
  • Fujii H, Shimizu M, Miyagi T, Kunihiro M, Tanaka R, ...
  • نمایش کامل مراجع